Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)

10 de noviembre de 2026 actualizado por: Mahidol University

Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study

This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).

Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.

In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.

The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.

The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.

Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.

The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.

The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.

The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

24

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Tanun Jitwatcharakomol, MD
  • Número de teléfono: +66 90 962 3000
  • Correo electrónico: tanun.jit@mahidol.ac.th

Copia de seguridad de contactos de estudio

  • Nombre: Natawat Sukumtanakul, MD
  • Número de teléfono: +66 90 985 6598
  • Correo electrónico: d.natawats@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
  • Status post breast-conserving surgery
  • Planned adjuvant breast-only radiotherapy
  • No indication for regional nodal irradiation
  • Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
  • Age ≥18 years

Exclusion Criteria:

  • Planned treatment using Deep Inspiration Breath Hold (DIBH)
  • Bilateral breast cancer
  • Previous radiotherapy to the ipsilateral breast
  • Unable to tolerate either the prone or supine position
  • Breast volume >750 cm³
  • Pre-existing heart disease or lung disease
  • Active connective tissue disease
  • Pregnant or found to be pregnant

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Supine and Prone Whole-Breast Radiotherapy Planning

All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability.

Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean Heart Dose in Supine Versus Prone Treatment Plans
Periodo de tiempo: within 4 weeks after both CT simulations

Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage.

within 4 weeks after both CT simulations
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Periodo de tiempo: within 4 weeks after both CT simulations

Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage.

within 4 weeks after both CT simulations

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
PTV_Eval V95 in Supine Versus Prone Treatment Plans
Periodo de tiempo: within 4 weeks after both CT simulations

PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%).

within 4 weeks after both CT simulations
Treatment time from initial setup to treatment completion
Periodo de tiempo: within 4 weeks after treatment completion

Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes.

within 4 weeks after treatment completion
translational X Positioning Accuracy
Periodo de tiempo: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Y Positioning Accuracy
Periodo de tiempo: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
translational Z Positioning Accuracy
Periodo de tiempo: within 4 weeks after treatment completion

Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm).

within 4 weeks after treatment completion
Patient Satisfaction Score
Periodo de tiempo: within 1 hours after both CT simulations, and within 1 hours after treatment completion

Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position.

within 1 hours after both CT simulations, and within 1 hours after treatment completion
Radiation Therapist Satisfaction
Periodo de tiempo: within 1 hours after treatment completion

Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique.

within 1 hours after treatment completion
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Periodo de tiempo: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity.

Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Tanun Jitwatcharakomol, MD, Mahidol University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

28 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir